GeneMind Biosciences Valuation, Funding & Investors

GeneMind Biosciences is valued at $573M as of March 2025.

Last GeneMind Biosciences valuation

$573M

Undisclosed stage · Mar 2025

Last GeneMind Biosciences funding round

$89M

Series D · Sep 2026

Cumulative funding GeneMind Biosciences raised

$204M

across 4 funding rounds

Key investors in GeneMind Biosciences

  • SZHTI Group
  • Voyagers Capital
  • Guangzhou Kingmed
  • Rongquan Venture Capital
  • Shuangye Venture Capital
  • Shenzhen Capital Group

GeneMind Biosciences Overview

About GeneMind Biosciences

GeneMind Biosciences produces third-generation single-molecule gene sequencing systems, delivering advanced tools for clinicians and researchers through ongoing technological breakthroughs.


Founded

2012

HQ

ChinaGuangzhou

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$573M (Mar 2025)

GeneMind Biosciences Valuation

GeneMind Biosciences is currently valued at $573M, based on its undisclosed-stage round in March 2025.

The $39M round included Guangzhou Kingmed, Voyagers Capital, JinHe Ziben, Rongquan Venture Capital, Qianhe Capital and 2 other investors.

GeneMind Biosciences' valuation has grown 1.0x from $557M at its Series B in September 2020 to $573M in March 2025, across 2 priced rounds.

GeneMind Biosciences valuation by funding round

GeneMind Biosciences valuation by funding round
DateStageValuation
Mar 2025Undisclosed stage$573M
Sep 2020Series B$557M

GeneMind Biosciences Funding History

GeneMind Biosciences has raised a total of $204M across 4 funding rounds.

GeneMind Biosciences' first fundraising round was a $21M Series B in September 2020. The most recent completed round was a $89M Series D in September 2026.

GeneMind Biosciences funding rounds

GeneMind Biosciences funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Sep 2026Series DChina Reform Fund Management (lead); Rongquan Venture Capital (lead); Shanghai International Group (SIG) (lead); Shenzhen Capital Group (lead); Xiangjiang State Investment; Voyagers Capital; Caixin Industry Fund; Guosheng Hongyuan; Delian Capital; SZHTI Group; Shuangye Venture Capital$89M-GeneMind Biosciences (真迈生物) completed a nearly RMB 600 million Series D financing on September 14, 2026. The round was led by Shanghai International Group Investment, Shenzhen Capital Group, Rongquan Venture Capital, and China Reform Fund Management, with participation from Caixin Industry Fund, Delian Capital, Guosheng Hongyuan, Shuangye Venture Capital, Xiangjiang State Investment, Guangtou Capital, Renxian Capital, Voyagers Capital, SZHTI Group, and others. The company said the proceeds will support technology innovation, industrialization delivery, and global market expansion, and will further expand its sequencing and multi-omics life-science tools platform. GeneMind is a Shenzhen-based sequencing technology company focused on DNA sequencing systems, reagents, and related life-science tools. The financing followed its Series C+ round completed in May 2025, and the company positioned the new capital toward product development, capacity expansion, regulatory progress, and overseas commercialization.
Mar 2025Undisclosed stageGuangzhou Kingmed; Voyagers Capital; JinHe Ziben; Rongquan Venture Capital; Qianhe Capital; Sansure Biotech; Shuangye Venture Capital$39M$573MGeneMind Biosciences is a biotech company that has raised a total of $252.97M across 9 funding rounds from 26 investors. The latest round identified is Series C - III on May 28, 2025, raising $38.89M from investors including Jinhe Capital (likely JinHe Ziben), KingMed Diagnostics, Sansure Biotech, Shengwei Rongquan (likely Rongquan Venture Capital), Qianhe Capital, Shuange Chuang Ventures (likely Shuangye Venture Capital), Voyagers Capital, Haikou Junxin, and undisclosed investors.
Aug 2023Series CGuoxin Investment (lead); Guangzhou Kingmed (lead); Caixin Capital; SZHTI Group; Changzhou Shuangye Venture Capital; Guochuang Zhiyuan$55M-GeneMind Biosciences is a genomics company developing third-generation single-molecule gene sequencing systems and platforms, founded in 2012, with a focus on expanding R&D for products and applications as well as international markets. The company has raised a cumulative $252.97M across 9 funding rounds from 26 investors, including multiple Series C tranches. Later rounds include Series C on 05/25/2022 and Series C - III on 05/28/2025 for $38.89M led by investors like Jinhe Capital and KingMed Diagnostics, plus a CNY 130M equity round expected on 03/07/2025. GeneMind continues international expansion, partnering with global players in sequencing as of 2025.
Sep 2020Series BSincere Capital (lead)$21M$557MGeneMind Biosciences is a biotechnology company focused on genomics and sequencing technologies, having raised a total of $252.97M across 9 funding rounds as of May 2025. The company has attracted 26 investors overall. A key early-stage round was a Series B on August 31, 2020, where it raised $20.5M led by Sincere Capital, with a post-money valuation of $557M, including later participants like Sansure Biotech, KingMed Diagnostics, and Voyagers Capital in its Series C - III round of $38.89M on May 28, 2025. The company's progression from Series B in 2020 to multiple Series C rounds by 2025 indicates sustained investor interest in its genomics platform amid China's growing biotech ecosystem.

Who has invested in GeneMind Biosciences?

20 investors have backed GeneMind Biosciences across its funding rounds, including SZHTI Group, Voyagers Capital, Guangzhou Kingmed, Rongquan Venture Capital, Shuangye Venture Capital and Shenzhen Capital Group.

Lead investors include China Reform Fund Management, Rongquan Venture Capital, Shanghai International Group (SIG), Shenzhen Capital Group, Guoxin Investment and 2 other investors.


GeneMind Biosciences Investors

Investors in GeneMind Biosciences by funding rounds participated
InvestorHQRoundsRoleFirst check
Guangzhou KingmedChinaGuangzhou2LeadAug 2023
Voyagers Capital--2ParticipantMar 2025
Rongquan Venture Capital--2LeadMar 2025
SZHTI GroupChinaShenzhen2ParticipantAug 2023
Shuangye Venture CapitalChinaChina2ParticipantMar 2025
Sincere CapitalChinaShanghai1LeadSep 2020
Xiangjiang State InvestmentChinaChangsha1ParticipantSep 2026
Caixin Industry FundChinaChangshan1ParticipantSep 2026
Guosheng HongyuanChinaShanghai1ParticipantSep 2026
Delian CapitalChinaBeijing1ParticipantSep 2026
China Reform Fund ManagementChinaChina1LeadSep 2026
JinHe ZibenChinaChina1ParticipantMar 2025
Caixin CapitalChinaHunan1ParticipantAug 2023

This data is available for Pro users. Sign up to see all 20 GeneMind Biosciences investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

GeneMind Biosciences Competitors

GeneMind Biosciences competitors include listed companies like Pacific Biosciences and Sansure Biotech, and private ones like Inscripta, Cellanome, Clear Labs and Genesis Healthcare.

Public and private companies comparable to GeneMind Biosciences
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
InscriptaUnited StatesUnited StatesPrivate--$565M-
CellanomeUnited StatesSan Francisco, CAPrivate--$525M-
Pacific BiosciencesUnited StatesUnited StatesPublicly listed$160M($153M)$429M5.6x
Clear LabsUnited StatesSan Francisco, CAPrivate--$413M-
Genesis HealthcareJapanJapanPrivate--$389M-
Sansure BiotechChinaChinaPublicly listed$245M$48M$1.4B4.1x

GeneMind Biosciences Public Comps

GeneMind Biosciences is still privately-owned, but its public comps include Fulgent Genetics, Scribe Therapeutics, OmniAb, Avacta Group, Eikon Therapeutics, Genfit, Pacific Biosciences, SOPHiA Genetics, Prenetics Global and Alpha Teknova.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Fulgent Genetics$323M($77M)1.1x1.1x(4.5x)(6.2x)
Scribe Therapeutics$51M($21M)14.2x-(34.0x)-
OmniAb$19M($47M)32.8x20.2x(13.0x)(18.4x)
Avacta Group$152K($38M)3242.0x184.3x(13.0x)(14.4x)
Eikon Therapeutics-($315M)--(0.6x)(0.5x)
Genfit$75M($98M)9.9x7.9x(7.7x)52.1x
Pacific Biosciences$160M($153M)5.6x5.6x(5.9x)(6.9x)
SOPHiA Genetics$77M($65M)8.8x7.5x(10.4x)(18.8x)

This data is available for Pro users. Sign up to see all GeneMind Biosciences competitors and their valuation data.

Start Free Trial

Common questions about GeneMind Biosciences

When was GeneMind Biosciences founded?GeneMind Biosciences was founded in 2012.
Where is GeneMind Biosciences headquartered?GeneMind Biosciences is headquartered in Guangzhou, China.
Is GeneMind Biosciences publicly listed?No, GeneMind Biosciences is a private, VC-backed company.
What is GeneMind Biosciences' valuation?GeneMind Biosciences was last valued at $573M in its undisclosed-stage round in March 2025.
How much funding has GeneMind Biosciences raised?GeneMind Biosciences has raised $204M across 4 funding rounds.
What was GeneMind Biosciences' last funding round?GeneMind Biosciences' last funding round was a $89M Series D in September 2026, led by China Reform Fund Management, Rongquan Venture Capital, Shanghai International Group (SIG) and Shenzhen Capital Group.
Who are GeneMind Biosciences' investors?GeneMind Biosciences' investors include Guangzhou Kingmed, Voyagers Capital, Rongquan Venture Capital, SZHTI Group, Shuangye Venture Capital, Sincere Capital, Xiangjiang State Investment, Caixin Industry Fund, Guosheng Hongyuan, Delian Capital and 10 others.
Which companies are comparable to GeneMind Biosciences?Companies comparable to GeneMind Biosciences include Inscripta, Cellanome, Pacific Biosciences, Clear Labs, Genesis Healthcare and Sansure Biotech.

See companies similar to GeneMind Biosciences

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial